



IFW 1639

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant No. : 09/852,910  
Applicant : Annette GILCHRIST  
Filed : May 11, 2001  
TC/A.U. : 1639  
Examiner : Teresa D. Wessendorf

Docket No. : 2661-101  
Customer No. : 06449  
Confirmation No. : 4758

INFORMATION DISCLOSURE STATEMENT


Director of the United States Patent  
and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449. Applicant believes no fee is due in connection with this submission but if the Office deems a fee is necessary, the Commissioner is hereby authorized to charge the fee to deposit account number 02-2135. An extra copy of this sheet is attached for that purpose.

Respectfully submitted,

By

  
Martha Cassidy  
Attorney for Applicants  
Registration No. 44,066  
ROTHWELL, FIGG, ERNST & MANBECK, P.C.  
Suite 800, 1425 K Street, N.W.  
Washington, D.C. 20005  
Telephone: (202) 783-6040

Enclosure(s) :  
PTO-1449 Form  
References



Attorney Docket Number | 2661-101


Sheet

1

of

4

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 				<i>Complete if Known</i>	
				Application Number	09/852,910
				Filing Date	May 11, 2001
				First Named Inventor	Annette GILCHRIST
				Group Art Unit	1639
				Examiner Name	Teresa D. Wessendorf
				Confirmation No.	4758
Sheet	2	of	4	Attorney Docket Number	2661-101

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
		WO	98/19162	A1	FOWLKES et al.	05-07-1998	
Examiner Signature						Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**



*Complete if Known*

Application Number	09/852,910
Filing Date	May 11, 2001
First Named Inventor	Annette GILCHRIST
Group Art Unit	1639
Examiner Name	Teresa D. Wessendorf
Confirmation No.	4758
Attorney Docket Number	2661-101


Sheet 3 of 4

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Barker et al., "Constitutively Active 5-Hydroxytryptamine <sub>2c</sub> Receptors Reveal Novel Inverse Agonist Activity of Receptor Ligands", J. Biol. Chem., 269(16):11687-11690, 1994.	
		Bertin et al., "Functional Expression of the Human Serotonin 5-HT <sub>1A</sub> Receptor in <i>Escherichia coli</i> ", J. Biol. Chem., 267(12):8200-8206, 1992.	
		Chidiac et al., "Inverse Agonist Activity of $\beta$ -Adrenergic Antagonists", Mol. Pharmacol., 45:490-499, 1994.	
		Costa and Herz, "Antagonists with negative intrinsic activity at $\delta$ opioid receptors coupled to GTP-binding proteins", Proc. Natl. Acad. Sci. USA, 86:7321-7325, 1989.	
		Costa et al., "Drug Efficacy at Guanine Nucleotide-Binding Regulatory Protein-Linked Receptors: Thermodynamic Interpretation of Negative Antagonism and of Receptor Activity in the Absence of Ligand", Mol. Pharmacol., 41:549-560, 1992.	
		Farfel et al., "The Expanding Spectrum of G Protein Diseases", New Engl. J. Med., 340(13): 1012-1020, 1999.	
		Flanagan et al., "Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions", Rev. of Reprod., 2:113-120, 1997.	
		Ford et al., "Molecular Basis for Interactions of G Protein $\beta\gamma$ Subunits with Effectors", Science, 280:1271-1274, 1998.	
		Gilchrist et al., "G $\alpha$ COOH-Terminal Minigene Vectors Dissect Heterotrimeric G Protein Signaling", Protocols: Science's STKE, 118, 2002. (Abstract only)	
		Greco et al. "Cancer Gene Therapy: 'Delivery, Delivery, Delivery'", Frontiers in Bioscience, 7:1516-1524, 2002.	
		Gromoll et al., "Functional and clinical consequences of mutations in the FSH receptor", Mol. and Cell. Endocrinol., 125:177-182, 1996.	
		Hasegawa et al. "Two Isoforms of the Prostaglandin E Receptor EP <sub>3</sub> Subtype Different in Agonist-independent Constitutive Activity", J. Biol. Chem., 271(4):1857-1860, 1996.	
		Inanobe et al., "Molecular cloning and characterization of a novel splicing variant of the Kir3.2 subunit predominantly expressed in mouse testis", J. Physiol., 521.1:19-30, 1999.	
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 				<i>Complete if Known</i>	
				Application Number	09/852,910
				Filing Date	May 11, 2001
				First Named Inventor	Annette GILCHRIST
				Group Art Unit	1639
				Examiner Name	Teresa D. Wessendorf
				Confirmation No.	4758
	4	of	4	Attorney Docket Number	2661-101

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
		Leeb-Lundberg et al., "Antagonists of Bradykinin That Stabilize a G-protein-uncoupled State of the B2 Receptor Act as Inverse Agonists in Rat Myometrial Cells", J. Biol. Chem., 269(42):25970-25973, 1994.		
		Lewin, B., "G proteins may activate or inhibit target proteins," Genes VII, Oxford University Press 2000, Chapter 26, pages 809-811.		
		Lipinski et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings", Adv. Drug Delivery Rev., 23:3-25, 1997.		
		Matsuoka et al., "Sequence analysis of cDNA and genomic DNA for a putative pertussis toxin-insensitive guanine nucleotide-binding regulatory protein $\alpha$ subunit", Proc. Natl. Acad. Sci. USA, 85:5384-5388, 1988.		
		Nielsen et al., "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide", Science, 254(5037):1497-1500, 1991. (Abstract only)		
		Pei et al., "A constitutively active mutant $\beta_2$ -adrenergic receptor is constitutively desensitized and phosphorylated", Proc. Natl. Acad. Sci. USA, 91:2699-2702, 1994.		
		Ren et al., "Constitutively Active Mutants of the $\alpha_2$ -Adrenergic Receptor", J. Biol. Chem., 268(22):16483-16487, 1993.		
		Samama et al., "Negative Antagonists Promote an Inactive Conformation of the $\beta_2$ -Adrenergic Receptor", Mol. Pharmacol., 45:390-394, 1994.		
		Tiberi and Caron, "High Agonist-independent Activity Is a Distinguishing Feature of the Dopamine D1B Receptor Subtype", J. Biol. Chem., 269(45):27925-27931, 1994.		
		Vanhauwe et al., "Thrombin Receptors Activate G <sub>o</sub> Proteins in Endothelial Cells to Regulate Intracellular Calcium and Cell Shape Changes", J. Biol. Chem., 277(37):34143-34149, 2002.		
		Vassart et al., "The G Protein-coupled Receptor Family and One of Its Members, the TSH Receptor <sup>an</sup> ", Ann. N.Y. Acad. Sci., 766:23-30, 1995.		
Examiner Signature			Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.